Replies to post #4890 on BioCryst Pharmaceuticals,Inc. (BCRX)

[Femto99]

More to come. The cost for PNH C5 inhibitor Ravulizumab provided lifetime per-patient cost reductions (discounted) of 32.4% and 35.5% vs eculizumab in adult and pediatric base cases, respectively. Total costs for ravulizumab vs eculizumab were $12,148,748 and $17,979,007, respectively, for adults, and $11,587,832 and $17,959,814, respectively, for children.
https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1831519#:~:text=Ravulizumab%20provided%20lifetime%20per%2Dpatient,%2417%2C959%2C814%2C%20respectively%2C%20for%20children.